Lung Cancer
Volume 70, Issue 1 , Pages 63-70 , October 2010

The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis

  • Sufeng Chen

      Affiliations

    • Department of Cardiothoracic Surgery, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600 Yishan Road, Shanghai 200233, People's Republic of China
    • These two authors contributed equally to this paper.
    • ,
  • Jie Zhang

      Affiliations

    • Department of Thoracic Surgery, Cancer Hospital of Fudan University, 399 Ling Lin Street, Shanghai 200032, People's Republic of China
    • These two authors contributed equally to this paper.
    • ,
  • Rui Wang

      Affiliations

    • Department of Thoracic Surgery, Cancer Hospital of Fudan University, 399 Ling Lin Street, Shanghai 200032, People's Republic of China
    • ,
  • Xiaoyang Luo

      Affiliations

    • Department of Thoracic Surgery, Cancer Hospital of Fudan University, 399 Ling Lin Street, Shanghai 200032, People's Republic of China
    • ,
  • Haiquan Chen

      Affiliations

    • Department of Cardiothoracic Surgery, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600 Yishan Road, Shanghai 200233, People's Republic of China
    • Department of Thoracic Surgery, Cancer Hospital of Fudan University, 399 Ling Lin Street, Shanghai 200032, People's Republic of China
    • Corresponding Author InformationCorresponding author at: Department of Thoracic Surgery, Cancer Hospital of Fudan University, 399 Ling Lin Street, Shanghai 200032, People's Republic of China. Tel.: +86 136 0197 3588; fax: +86 21 5635 3642.

Received 24 October 2009 ,Revised 1 May 2010 ,Accepted 7 May 2010.

References 

  1. Garcia M, Jemal A, Ward E, Center M, Hao Y, Siegel R, et al. In: Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007;available at: http://www.cancer.org/docroot/STT/stt_0.asp. Accessed July 22, 2009
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249
  3. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1997;15:2996–3018
  4. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330–353
  5. Bidoli P, Zilembo N, Cortinovis D, Mariani L, Isa L, Aitini E, et al. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology Study. Ann Oncol. 2007;18:461–467
  6. Vilmar A, Sorensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009;64:131–139
  7. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol. 2000;20:7980–7990
  8. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol. 2004;24:5776–5787
  9. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res. 2005;11:6100–6102
  10. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19:4298–4304
  11. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478:23–43
  12. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, et al. Ribonucleotide reductase messenger rna expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Res. 2004;10:1318–1325
  13. Olaussen KA, Mountzios G, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med. 2007;13:284–289
  14. Zirlik S, Lampert S, Hahn EG, Wiest GH, Bruckl WM. An approach to individualised therapy of non-small cell ling carcinoma (NSCLC) – relevance of molecular predictive and prognostic factors. Pneumologie. 2007;61:731–740
  15. Danzinger S, Filipits M. Biomarkers – the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC). Wien Med Wochenschr. 2007;157:554–561
  16. Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer. 2008;113:1379–1386
  17. Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer. 2008;59:377–384
  18. Wachters FM, Wong LSM, Timens W, Kampinga HH, Groen HJM. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer. 2005;50:211–219
  19. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol. 2007;2:902–906
  20. Jeong SH, Jung JH, Han JH, Kim JH, Choi YW, Lee HW, et al. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer. 2009;[Epub ahead of print]
  21. Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 2007;98:1336–1343
  22. Holm B, Mellemgaard A, Skov T, Skov BG. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol. 2009;27:4254–4259
  23. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2003;available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed September 25, 2009
  24. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100:1385–1392
  25. The Cochrane Collaborative Review Group on HIV Infection and AIDS. Editorial Policy: Inclusion and Appraisal of Experimental and Non-experimental (Observational) Studies. 2009;available at: http://www.igh.org/Cochrane. Accessed September 29, 2009
  26. Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, et al. Expression of ERCC1 and class III (beta)-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer. 2009;64:326–333
  27. Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L. Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer. Ai Zheng. 2004;23:845–850
  28. Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer. 2009;65:377–382
  29. Li GF, Wang WW, Jiang YX, Wang Q, Cheng N, Guo G. Relationship between ERCC1 expression and cisplatin resistance in non-small cell lung cancer. Chin J Prev Treat. 2008;15:1483–1485
  30. Liu J, Ma Z, Xue Z, Tang L, Tang Y, Lv J. Relationship between the expression of ERCC1 and the curative effect of chemotherapy in the patients with nonsmall-cell lung cancer in late stage. J Pract Med. 2008;24:2551–2554
  31. Lord RVN, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERRC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Res. 2002;8:2286–2291
  32. Monzo M, Rosell R, Taron M. Drug resistance in non-small cell lung cancer. Lung Cancer. 2001;34:S91–S94
  33. Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 2009;64:98–104
  34. Shan L, Han ZG, Liu L, Aerxiding P, Wang XG, Ma L, et al. ERCC1 and BRCA1 expressions in advanced non-small cell lung cancer and their relationship with cisplatin resistance. Tumor. 2009;29:571–574
  35. Wang X, Zhao J, Yang L, Mao L, An T, Bai H, et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol. 2009;[Epub ahead of print]
  36. Xiao Y, Song Y, Shi Y. ERCC1 and class III (beta)-tubulin protein expression in relation to tumour response and survival of stage IIIB/IV NSCLC patients treated with TP/NP chemotherapy regimens. Chin J Lung Cancer. 2009;12:82–85
  37. Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA. 2008;300:1674–1684
  38. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25:2747–2754
  39. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995;13:1221–1230
  40. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006;1:441–446
  41. Wakelee HA, Brahmer JR, Siegfried JM. Sex as a Determinate in Treatment Decisions for Non-small Cell Lung Cancer. ASCO Educational book. 2007;p. 395–399
  42. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 2002;62:2141–2150
  43. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel – cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15:1194–1203
  44. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;10:4939–4943
  45. Park SY, Hong YC, Kim JH, Kwak SM, Cho JH, Lee HL, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol. 2006;23:489–498
  46. Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?. Br J Cancer. 2007;97:145–151
  47. Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer. 2007;56:281–288
  48. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10:118–123
  49. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27:3540–3546
  50. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Res. 2008;14:1797–1803
  51. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356:800–808
  52. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634

PII: S0169-5002(10)00225-4

doi: 10.1016/j.lungcan.2010.05.010

Lung Cancer
Volume 70, Issue 1 , Pages 63-70 , October 2010

Article Tools

* Image Usage & Resolution